Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborative Group.

Journal article

Assessing combined anti-platelet therapy in suspected acute myocardial infarction Aspirin has been shown to be effective in the emergency treatment of acute myocardial infarction. It irreversibly inhibits platelet cyclo-oxygenase and thereby prevents the formation of the platelet aggregating agent thromboxane A2. Clopidogrel is an anti-platelet agent that acts by a different mechanism, inhibiting adenosine diphosphate-induced platelet aggregation. Simultaneous inhibition of both of these path...

Expand abstract

Authors: Second Chinese Cardiac Study (CCS-2) Collaborative Group

• Publication status: Published
• Journal: Journal of cardiovascular risk
• Volume: 7
• Issue: 6
• Pages: 435-441
• Publication date: 2000-12-01
• ISSN: 1350-6277
• Language: English
• Keywords: Myocardial Infarction; Second Chinese Cardiac Study (CCS-2) Collaborative Group; Ticlopidine; Aspirin; Adrenergic beta-Antagonists; Metoprolol; Anti-Inflammatory Agents, Non-Steroidal; Platelet Aggregation Inhibitors; Research Design; Drug Therapy, Combination; Humans; China